• National Taiwan University
• Baylor College of medicine, USA. PhD.

• Contributing Physician, Taipei Veterans General Hospital

• Professor of internal medicine, Faculty of medicine, National Yang Ming Chiao Tung University

• Cardiology fellowship training in UCLA, USA
• Chief resident training in cardiology in Taipei Veterans General Hospital
• Resident training in interna; medicine in Taipei Veterans General Hospital

•  License of physician, Taiwan

• Coronary artery diseease
• Coronary and peripheral  Intervention
• Familial Hypercholesterolemia
• Pulmonarpey hyrtension
• Hypertrophy cardiomyopathy
• Cardiovascular genetics

• mjcharng@vghtpe.gov.tw

1. Li YH, Yeh HI, Jeng JS, Charng MJ. Comparison of the 2017 Taiwan Lipid Guidelines and the Western Lipid Guidelines for High Risk Patients. J Chin Med Assoc 2018;81:853-9.
2. Huang CC, Charng MJ. Clinical evaluation of evolocumab for the treatment of homozygous familial hypercholesterolemia in Chinese patients. Ther Clin Risk Manag 2019;15:1209-16.
3. Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng MJ, Pordy R, Donahue S, Ali S, Dong Y, Khilla N, Banerjee P, Baccara-Dinet M, Rosenson RS. Efficacy and safety of alirocumab in adults with homozygous  familial hypercholesterolemia: The ODYSSEY HoFH trial. J Am Coll Cardiol 2020;76:131-142.
4. Huang CC and Charng MJ. Genetic diagnosis of familial hypercholesterolemia in Asia. Front. Genet. 2020;11:833. doi: 10.3389/fgene.2020.00833.
5. Huang CC, Niu DM, Charng MJ. Genetic analysis in a Taiwanese cohort of 750 index patients with clinically diagnosed familial hypercholesterolemia. J Atheroscler Thromb 2022;29:639-53.

限於篇幅,以上謹為代表著作